Table I.
Association of miR-195/PRR11 expression and the clinicopathological features of the prostate cancer (PCa) patients.
| hsa-miR-195/PRR11 | |||||
|---|---|---|---|---|---|
| N | miR-195 high/PRR11 low (n=42) | Others (n=42) | miR-195 low/PRR11 high (n=27) | P-value | |
| Mean age (years) | 111 | 58.57±6.17 | 57.34±8.07 | 59.48±8.45 | 0.495 |
| Preoperative PSA (ng/ml) | |||||
| <4 | 26 | 9 (34.6) | 14 (53.8) | 3 (11.5) | 0.126 |
| ≥4 | 83 | 33 (39.8) | 28 (33.7) | 22 (26.5) | |
| Gleason score | |||||
| <8 | 87 | 38 (43.7) | 34 (39.1) | 15 (17.2) | 0.005 |
| ≥8 | 17 | 3 (17.6) | 5 (29.4) | 9 (52.9) | |
| Clinical stage | |||||
| <T2A | 64 | 23 (35.9) | 24 (37.5) | 17 (26.6) | 0.456 |
| ≥T2A | 43 | 18 (41.9) | 18 (41.9) | 7 (16.3) | |
| Pathological stage | |||||
| T2A-T2C | 69 | 31 (44.9) | 24 (34.8) | 14 (20.3) | 0.197 |
| T3A-T4 | 37 | 10 (27) | 17 (45.9) | 10 (27) | |
| Metastasis | |||||
| Negative | 93 | 40 (43) | 37 (39.8) | 16 (17.2) | <0.001 |
| Positive | 18 | 2 (11.1) | 5 (27.8) | 11 (61.1) | |
| Biochemical recurrence | |||||
| Negative | 80 | 38 (47.5) | 29 (36.3) | 13 (16.3) | 0.003 |
| Positive | 25 | 3 (12) | 12 (48) | 10 (40) | |
| Overall survival | |||||
| Alive | 99 | 38 (38.4) | 40 (40.4) | 21 (21.2) | 0.07 |
| Died | 12 | 4 (33.3) | 2 (16.7) | 6 (50.0) | |
PSA, prostate-specific antigen.